Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trial of GM-CSF for Alveolar Proteinosis
NCT00030056Phase 2Terminated
- Sponsor
- Cleveland Clinic
- Start
- Sep 2001
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary alveolar proteinosis (PAP) comparing GM-CSF with Placebo (2 arms). Primary endpoint: Clinical response at 6 months. Started Sep 2001; status: terminated.
02
Drugs
sargramostim
03
Conditions
pulmonary alveolar proteinosis (PAP)
Beyond the preview
Go deeper on NCT00030056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030056.